DiagnaMed Expands with Drug and Clinical Research AI Platform

BRAIN AGE® Brain Health AI Platform - DiagnaMed Holdings Corp is expanding the use of its BRAIN AGE® Brain Health AI Platform by leveraging EEG data from research studies and future data collection to build a potential drug discovery and clinical research AI platform [1] - BRAIN AGE® estimates brain age by recording brain-wave activity from multiple brain regions and calculating the data with a proprietary machine-learning model [2] - The platform can assess if a brain is aging more quickly or slowly than typical for healthy individuals and can evaluate brain health by scoring brain resilience, vulnerability, and performance functions [2] - BRAIN AGE® has the potential to accelerate patient recruitment for clinical trials, data analysis, drug development decisions, and new treatment options for neurological, psychiatric, and infectious diseases [1] Clinical Applications and Validation - BRAIN AGE® can classify and identify drugs according to their mechanism of action on brain activity, which is useful for developing novel drug analogs and potential drug repurposing ideas [2] - The platform can be used as an inexpensive way to screen large numbers of people for vulnerability to age-related cognitive decline and to test the effectiveness of medications and lifestyle changes [3] - A peer-reviewed paper in Frontiers in Neuroergonomics highlights the effectiveness of BRAIN AGE® for large-scale screening and brain optimization using a low-cost EEG headset [3] Company Overview - DiagnaMed Holdings Corp is a healthcare technology company focused on brain health using AI, commercializing the BRAIN AGE® Brain Health AI Platform, which estimates brain age and provides a brain health score [4] - The company is leveraging its proprietary EEG data to accelerate clinical trial development and discover potential novel treatments for neurological, psychiatric, and infectious diseases [1]